BioAegis Therapeutics Completes Over-Subscribed Financing for COVID-19 Trial
23 juin 2020 17h21 HE
|
BioAegis Therapeutics
MORRISTOWN, N.J., June 23, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical-stage private company focused on developing therapies for infectious, inflammatory and degenerative...
American BriVision Announces Completed Patient Enrollment in Clinical Trial at UCSF for Treatment of Adult ADHD
15 juin 2020 09h00 HE
|
American BriVision Holding Corporation
Patient enrollment has been completed for a Phase II Part I clinical trial at the University of California, San Francisco (UCSF) Medical Center Primary objective of Phase II Part I clinical trial is...
First Patient Treated in Phase 1 Clinical Trial Of Incysus Therapeutics Gamma Delta (γδ) T Cell Immunotherapy for Patients With Newly Diagnosed Glioblastoma
02 juin 2020 07h00 HE
|
Incysus Therapeutics, Inc.
NEW YORK, June 02, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Vyriad Inc. to Present Clinical Trial Updates for its Oncolytic Virotherapies at Virtual 2020 ASCO Annual Meeting
29 mai 2020 07h30 HE
|
Vyriad
ROCHESTER, Minn., May 29, 2020 (GLOBE NEWSWIRE) -- Vyriad, Inc. announced today that it will present data and information about the design of clinical trials evaluating its oncolytic viruses at the...
Zynerba Pharmaceuticals Announces Positive Top Line Results from Exploratory Open Label Phase 2 BRIGHT Trial of Zygel in Autism Spectrum Disorder
27 mai 2020 06h45 HE
|
Zynerba Pharmaceuticals, Inc.
- The BRIGHT Trial Achieved Statistically Significant and Clinically Meaningful Improvements from Baseline in All Subscales of the Aberrant Behavior Checklist - - Safety Data Reinforce...
Aeglea BioTherapeutics Announces 1-Year Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 6th Congress of the European Academy of Neurology
26 mai 2020 08h30 HE
|
Aeglea BioTherapeutics, Inc.
Pegzilarginase Showed Durable Clinical Response at 56 Week Analysis All Patients Demonstrated a Marked and Sustained Reduction in Plasma Arginine Favorable Safety Profile, Consistent with...
Samumed Announces Publication of Phase 2 Data on Lorecivivint, Now in Pivotal Trials for Knee Osteoarthritis
22 mai 2020 09h00 HE
|
Samumed, LLC.
SAN DIEGO, May 22, 2020 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today the publication of results from the Phase 2a trial of lorecivivint, an investigational CLK/DYRK1A inhibitor that modulates...
Surface Oncology and Merck to Collaborate on Immuno-Oncology Study Evaluating SRF617, Targeting CD39 in Combination with KEYTRUDA® (pembrolizumab) in Solid Tumor Patients
20 mai 2020 07h05 HE
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., May 20, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
HalioDx's expertise applied to ImCheck’s EVICTION Trial
19 mai 2020 07h50 HE
|
HalioDx
HalioDx to Characterize the Immune Contexture ofPatients Enrolled in ImCheck’s EVICTION Phase 1/2 Clinical Trial HalioDx’s immunoscoring technologies to characterize patients treated with ImCheck’s...
Fluidigm to Present at Upcoming Health Care Investor Conferences
13 mai 2020 16h02 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., May 13, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...